What Is CJC-1295

CJC-1295 is a synthetic peptide consisting of 29 amino acids that functions as a modified analog of growth hormone-releasing hormone (GHRH). It was designed to resist enzymatic degradation and extend the duration of growth hormone release from the anterior pituitary gland. Two forms circulate in clinical and research settings: one conjugated with a Drug Affinity Complex (DAC) for prolonged activity, and one without DAC (often called modified GRF 1-29) for shorter, pulsatile stimulation.

Growth hormone output declines steadily with age, dropping by roughly half between early adulthood and middle age. This decline is associated with reductions in lean muscle mass, increases in visceral adiposity, slower tissue repair, and changes in bone mineral density. Because growth hormone influences protein synthesis, fat metabolism, and cellular regeneration, the age-related decline has drawn sustained interest from longevity researchers and clinicians.

CJC-1295 sits within a broader category of growth hormone secretagogues, compounds that stimulate endogenous GH production rather than supplying it directly. The appeal is straightforward: if the pituitary gland can still produce growth hormone but is receiving less stimulatory input from hypothalamic GHRH, a synthetic GHRH analog might restore some of that signaling. Whether restoring youthful GH levels actually extends healthspan or lifespan in humans remains an open question, but the mechanistic rationale has generated ongoing research into peptides like CJC-1295.

CJC-1295 binds to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland. This receptor is a G-protein coupled receptor that, upon activation, triggers an intracellular cascade involving cyclic AMP (cAMP). The rise in cAMP activates protein kinase A, which promotes both the synthesis and secretion of growth hormone. In this regard, CJC-1295 mimics the action of endogenous GHRH but with structural modifications that slow its breakdown by dipeptidyl peptidase IV (DPP-IV), an enzyme that rapidly degrades native GHRH in the bloodstream.

The DAC-conjugated version adds a second layer of stability. The Drug Affinity Complex allows the peptide to bind covalently to serum albumin after injection. This albumin binding dramatically extends the circulating half-life, creating a sustained elevation of growth hormone over days rather than minutes. The result is a more tonic, continuous pattern of GH secretion. The non-DAC form, by contrast, is cleared quickly and tends to produce discrete GH pulses more akin to the body's natural ultradian rhythm. This difference matters because pulsatile GH release is how the hypothalamic-pituitary axis normally operates, and there is debate about whether tonic versus pulsatile elevation produces different downstream effects on IGF-1 signaling and receptor sensitivity.

Once growth hormone is released, it travels to the liver and other tissues, where it stimulates production of insulin-like growth factor 1 (IGF-1). IGF-1 mediates many of the anabolic and metabolic effects commonly attributed to growth hormone, including increased protein synthesis, enhanced lipolysis, and support of connective tissue maintenance. CJC-1295 also preserves the negative feedback loop: when GH and IGF-1 levels rise sufficiently, somatostatin release from the hypothalamus attenuates further GH secretion, providing a partial safety brake that exogenous GH injections bypass.

CJC-1295 is available in two primary forms distinguished by the presence or absence of the Drug Affinity Complex. CJC-1295 with DAC is a longer-acting variant designed for less frequent injection, typically once or twice per week. CJC-1295 without DAC, commonly marketed as modified GRF(1-29) or mod GRF, has a much shorter half-life and is usually injected one to three times daily, often paired with a growth hormone releasing peptide like Ipamorelin for synergistic effect.

Both forms are supplied as lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water before subcutaneous injection. The reconstituted solution must be refrigerated and is typically used within a few weeks. Oral and intranasal forms are not reliably available, and peptide bonds would be degraded in the gastrointestinal tract, making oral administration impractical. Some compounding pharmacies offer pre-mixed, ready-to-inject formulations, though these are less common.

Dosing protocols for CJC-1295 vary considerably among practitioners and lack standardization from controlled trials. For the non-DAC form (modified GRF 1-29), doses in the range of 100 to 300 micrograms per injection are commonly cited, administered one to three times daily, with the evening dose timed to coincide with natural nocturnal GH secretion. The DAC form is typically used at higher absolute doses, often 1 to 2 milligrams once or twice per week, reflecting its extended half-life.

When combined with Ipamorelin, both peptides are often dosed at comparable microgram levels per injection. The rationale for combination dosing is to activate two distinct receptor pathways simultaneously, amplifying GH release beyond what either agent achieves alone. Practitioners who use these peptides generally start at the lower end and adjust based on IGF-1 blood levels, clinical response, and side effects. There is no consensus on optimal cycle length; protocols ranging from 8 to 12 weeks with breaks of several weeks are common but not evidence-based in a rigorous sense.

Because CJC-1295 is not an FDA-approved pharmaceutical, sourcing from a licensed compounding pharmacy that follows current Good Manufacturing Practice (cGMP) standards is the most reliable way to ensure product integrity. Certificates of analysis (COA) from independent, third-party laboratories should accompany any peptide product, verifying identity, purity (typically above 98%), and the absence of bacterial endotoxins or heavy metals.

Key red flags include products sold without COAs, suppliers operating outside regulatory frameworks, and vials that arrive partially degraded or discolored. Legitimate lyophilized peptide should appear as a white to off-white powder with no visible clumping or discoloration. The peptide market includes research-grade products not intended for human use; these may carry lower purity standards and less rigorous testing. Provenance from a pharmacy that requires a prescription offers an additional, though imperfect, layer of quality assurance.

Clinical research on CJC-1295 is limited in scope. A small number of human studies, conducted primarily in the mid-2000s, demonstrated that both the DAC and non-DAC forms significantly increase circulating GH and IGF-1 levels after subcutaneous injection, with effects sustained for several days in the DAC variant. These pharmacokinetic and pharmacodynamic studies confirmed the peptide's basic mechanism, showing dose-dependent elevations in GH pulsatility and mean GH concentrations. However, these trials were short-term and focused on hormonal endpoints rather than clinical outcomes like body composition, physical performance, or longevity markers.

No large, long-term randomized controlled trials have evaluated CJC-1295 for anti-aging or healthspan outcomes. Much of the evidence cited in clinical practice is extrapolated from the broader literature on growth hormone replacement in GH-deficient adults, which shows improvements in lean mass, fat reduction, and bone density. Whether these benefits translate to GH-sufficient individuals seeking optimization remains unproven. The theoretical concern that chronically elevated IGF-1 could promote tumorigenesis comes from epidemiological data linking high-normal IGF-1 levels to increased cancer incidence, though this association has not been studied specifically in the context of CJC-1295 use. Animal data on GHRH analogs shows metabolic and body composition benefits, but species differences limit direct extrapolation.

Common side effects include injection site irritation, facial flushing, headache, water retention, and transient paresthesia. The sustained IGF-1 elevation produced by the DAC form raises particular caution around potential promotion of existing neoplasms, as IGF-1 is a known mitogenic signal. Joint pain and carpal tunnel-like symptoms, well-documented with exogenous GH use, have been reported anecdotally with CJC-1295. Because the peptide is not FDA approved for any indication, quality control and purity vary among suppliers, and contamination or mislabeling is a documented concern in the peptide market. Individuals with a history of cancer, pituitary disorders, or active malignancy are generally counseled against use by practitioners familiar with these compounds.